Stereotaxis announced recently that it hosted a demonstration of the GenesisX robotic system at this year’s Heart Rhythm Society (HRS) meeting (24–27 April, San Diego, USA), marking the first live, public demonstration of the technology and offering HRS attendees a glimpse into its “revolutionary” clinical capabilities and ‘weekend installation’.
According to Stereotaxis, GenesisX represents the latest advance in endovascular surgical robotics, building upon the proven benefits of robotic magnetic navigation while significantly enhancing accessibility for healthcare providers.
The system features a compact and efficient design, incorporating magnetic shielding into its structure to eliminate the need for room-based shielding, reducing infrastructure requirements. GenesisX operates on standard 120/230V power, requires no structural anchoring, and features an 80% smaller system cabinet that conveniently fits under an operating room table. Stereotaxis claims that the system’s smaller and lighter design enhances workflow efficiency while maintaining “the highest standards” in speed and responsiveness.
“We are thrilled to bring GenesisX to HRS, and allow the electrophysiology community to experience firsthand this cutting-edge innovation along with our expanding portfolio of proprietary catheters and digital technologies,” said David Fischel, Stereotaxis chairman and chief executive officer (CEO).
GenesisX obtained CE-mark approval in Europe in 2024 and is currently under review for US Food and Drug Administration (FDA) 510(k) clearance in the USA.
